FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer.

Publication/Presentation Date

10-27-2025

Abstract

Despite the advancement in therapies, ovarian cancer treatment is challenging due to poor prognosis and high relapse associated with acquired resistance. Targeting overexpression of FOLR1 in ovarian cancers has proven to be an attractive strategy. The recent FDA approval of FOLR1 targeted antibody drug conjugate has shown promising results albeit resistance with repeated use appears inevitable. Emerging targeted alpha-particle therapies, particularly Actinium-225 (

ISSN

2692-8205

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

41279140

Department(s)

Administration and Leadership

Document Type

Article

Share

COinS